Mesothelioma

Malignant pleural mesothelioma (MPM) is an aggressive, almost universally fatal cancer arising from the mesothelial lining of the pleural cavity. It is caused by asbestos exposure in roughly 95% of cases, carries a latency period of 20–50 years from first exposure to diagnosis, and has historically carried a median survival under 18 months. New immunotherapy combinations have begun to shift those odds for some patients, but the disease remains one of oncology's most difficult challenges — compounded by a long latency that means new cases will continue to appear for decades even as asbestos bans spread globally.

Table of Contents

1. Overview
2. Asbestos Causation & Latency
3. Clinical Presentation
4. Staging
5. Diagnosis & Pathology
6. Treatment
7. Prognosis & Survival
8. Legal, Occupational & Compensation
9. References
10. Connections
11. Featured Videos

Overview

Malignant mesothelioma is a cancer of the mesothelium — the thin layer of specialized cells lining the body's major cavities and internal organs. The pleural cavity (the space between the lungs and the chest wall) is involved in approximately 90% of cases, earning the disease its most familiar name: malignant pleural mesothelioma (MPM). The peritoneum accounts for roughly 7–10% of cases; the pericardium and tunica vaginalis testis are each affected in less than 1% of cases.

Globally, an estimated 30,000–40,000 new mesothelioma cases are diagnosed each year, with the United States seeing approximately 2,500–3,000 cases annually. Incidence peaked in the US and Western Europe in the 1990s–2000s following the high-exposure decades of the 1940s–1970s, when asbestos use in construction, shipbuilding, and manufacturing was unrestricted. In countries with ongoing asbestos use — notably Russia, China, India, and parts of Southeast Asia — incidence is projected to peak later in the 21st century.

MPM grows diffusely along the pleural surfaces rather than as a single discrete mass, which makes complete surgical excision technically difficult and contributes to its aggressive behavior. Tumor encasement of the lung and invasion into the chest wall, mediastinum, and diaphragm are hallmarks of advanced disease. Despite decades of clinical research, the prognosis remains poor for the majority of patients, though targeted immunotherapy introduced in 2020–2021 has produced meaningful survival improvements in a subset.

Back to Table of Contents

Asbestos Causation & Latency

Asbestos is the overwhelming cause of mesothelioma, responsible for approximately 95% of all cases. The term "asbestos" encompasses six naturally occurring silicate minerals classified into two fiber groups:

• Amphiboles — amosite (brown asbestos), crocidolite (blue asbestos), tremolite, anthophyllite, actinolite. Amphibole fibers are thin, straight, and biopersistent; they penetrate deep into the pleural tissue and are cleared very slowly, driving chronic inflammation and DNA damage. Crocidolite carries the highest mesothelioma risk per fiber.
• Chrysotile (white asbestos) — curly, more easily cleared by mucociliary mechanisms. Used in over 90% of commercial asbestos applications globally. Chrysotile is still mesothelioma-causative, but is somewhat less potent per fiber than amphiboles. Industry-funded research disputing chrysotile's carcinogenicity is not supported by independent epidemiology.

There is no safe dose of asbestos for mesothelioma risk. Even brief bystander or para-occupational exposure — a spouse shaking out an asbestos worker's work clothes, a child playing near an insulation job site — has caused mesothelioma. The latency period between first exposure and diagnosis ranges from 20 to 50 years, with a median near 40 years. This long latency means patients diagnosed today were typically exposed in the 1970s–1980s.

High-risk occupations historically include: shipyard workers, boilermakers, pipefitters, insulation installers, construction tradespeople, brake mechanics (chrysotile in friction pads), and military personnel (US Navy ships were heavily insulated with asbestos through the 1970s).

Genetic susceptibility — BAP1 cancer syndrome: Germline loss-of-function mutations in BAP1 (BRCA1-associated protein-1, a tumor suppressor on chromosome 3p21) are found in 1–2% of mesothelioma patients and define the BAP1 cancer syndrome. Affected families show elevated rates of mesothelioma, uveal melanoma, cutaneous melanoma, clear-cell renal cell carcinoma, and intrahepatic cholangiocarcinoma. Paradoxically, BAP1-mutant mesotheliomas carry a somewhat better prognosis than sporadic cases, possibly because they arise in a background of impaired homologous recombination that may enhance immunogenicity.

Other rare causes:

• Erionite — a naturally occurring zeolite mineral found in volcanic rock in parts of Turkey (Cappadocia region), where mesothelioma rates in affected villages are 1,000-fold above background. Also found in certain western US regions.
• Therapeutic radiation — prior chest or mediastinal irradiation (e.g., for lymphoma) can rarely produce mesothelioma, typically decades later.
• Simian virus 40 (SV40) — early polio vaccines (1955–1963) were contaminated with SV40. The virus is a potent mesothelial carcinogen in animal models and has been detected in human mesothelioma tissue in some studies. Whether SV40 is genuinely causative in humans remains controversial; epidemiological studies have not shown a clear increased mesothelioma rate in vaccinated cohorts.

Back to Table of Contents

Clinical Presentation

MPM has an insidious onset. Patients often tolerate symptoms for many months before seeking care, and the early signs are nonspecific. By the time the diagnosis is established, most patients have locally advanced disease.

Cardinal symptoms of pleural mesothelioma:

• Dyspnea — the most common presenting symptom, caused by large pleural effusion compressing the ipsilateral lung. Often the chief complaint at first medical contact.
• Chest pain — characteristically dull, aching, and persistent rather than pleuritic (sharp, positional). As disease advances and tumor invades the chest wall and intercostal nerves, pain becomes severe and difficult to control.
• Pleural effusion — present in over 90% of patients at diagnosis. The effusion is exudative, often hemorrhagic, and may be large enough to cause complete white-out of the affected hemithorax on chest X-ray. Fluid re-accumulates rapidly after thoracentesis.
• Constitutional symptoms — fatigue, anorexia, and weight loss typically accompany advanced disease.

Radiographic distinction from primary lung cancer: MPM grows diffusely along pleural surfaces, producing circumferential pleural thickening that encases the lung ("rind-like" or "peel-like" appearance on CT). This is in contrast to primary lung cancer, which typically forms a discrete parenchymal nodule or mass. Crucially, in MPM with massive pleural disease, the mediastinum may shift toward the affected side — a paradoxical finding explained by tumor encasement contracting and fixing the ipsilateral lung. Conventional pleural effusion shifts the mediastinum away; the absence of this contralateral shift in a large effusion should raise suspicion for MPM.

Peritoneal mesothelioma: Presents with progressive abdominal distension (ascites), diffuse abdominal pain, early satiety, nausea, and changes in bowel habit. Constitutional symptoms are prominent. A peritoneal primary without a pleural component in a patient without asbestos exposure should prompt consideration of the BAP1 cancer syndrome or erionite exposure.

Physical examination: Dullness to percussion and absent breath sounds over the effusion; tracheal deviation toward the affected side in the setting of extensive pleural encasement; digital clubbing and hypoxia in advanced cases.

Back to Table of Contents

Staging

MPM is staged using the AJCC/UICC TNM system. Because mesothelioma grows diffusely rather than as a discrete mass, T staging reflects the extent of pleural involvement and invasion into adjacent structures rather than tumor diameter.

T (Primary tumor) staging:

• T1 — tumor involves the ipsilateral parietal pleura (with or without involvement of the visceral, mediastinal, or diaphragmatic pleura on the same side, but no involvement of the visceral pleura surface facing the lung).
• T2 — tumor involves ipsilateral pleural surfaces with at least one of: involvement of the diaphragmatic muscle, extension to the lung's visceral pleural surface, or confluent visceral pleural tumor (including the fissures).
• T3 — tumor is locally advanced but potentially resectable. At least one of: chest wall involvement (focal, not transmural), endothoracic fascia, pericardium (non-transmural), solitary/focally resectable pericardial involvement, mediastinal fat.
• T4 — tumor is technically unresectable. Diffuse or multifocal chest wall invasion; direct transdiaphragmatic extension to the peritoneum; direct extension to the contralateral pleura; direct extension to mediastinal organs; direct extension to the spine; extension through the pericardium (with or without pericardial effusion); or involvement of the myocardium.

N (Regional lymph nodes): N0 = no regional node metastasis; N1 = ipsilateral bronchopulmonary, hilar, or mediastinal nodes; N2 = contralateral mediastinal, ipsilateral or contralateral supraclavicular nodes.

M (Distant metastasis): M0 = no distant metastasis; M1 = distant metastasis present.

Overall stage groupings: Stage I (T1N0M0) and Stage II (T2N0M0) are potentially resectable. Stage III (T3 or N1) may be resectable in selected centers. Stage IV (T4 or M1) is unresectable.

In practice, the majority of patients (60–80%) present with Stage III or IV disease, and resectability is limited to a minority even among those with earlier-stage findings.

Back to Table of Contents

Diagnosis & Pathology

Diagnosis requires tissue biopsy. Cytology from pleural fluid alone is insufficient — it has a sensitivity of only 25–30% for MPM, and current guidelines require histological confirmation in almost all cases.

Biopsy approaches:

• CT-guided needle biopsy — suitable for smaller pleural nodules or thickening. Provides a core of tissue for histology and immunohistochemistry (IHC), but sampling error is a concern for heterogeneous tumors.
• Medical thoracoscopy (pleuroscopy) — the preferred approach when feasible. Allows direct visualization of pleural surfaces, targeted biopsy of suspicious areas, and simultaneous pleurodesis. Provides larger, better-oriented specimens and higher diagnostic yield (over 90%).
• Video-assisted thoracoscopic surgery (VATS) — used when thoracoscopy is inconclusive or a larger sample is needed for definitive subtyping.

Histological subtypes (critical for prognosis and treatment selection):

• Epithelioid (70% of cases) — cuboidal or columnar cells arranged in tubular, papillary, or solid patterns. Best prognosis; most responsive to systemic therapy including immunotherapy.
• Sarcomatoid (15–20%) — spindle cells resembling a sarcoma. Worst prognosis (median survival under 6 months with any treatment); largely unresponsive to immunotherapy due to low PD-L1 expression and immune-cold microenvironment. Desmoplastic mesothelioma is a sarcomatoid variant especially difficult to distinguish from reactive pleural fibrosis.
• Biphasic/mixed (10–15%) — contains both epithelioid and sarcomatoid components. Prognosis intermediate; sarcomatoid proportion correlates inversely with survival.

Immunohistochemistry (IHC) panel for diagnosis: No single marker is 100% specific, so a panel is used.

• Positive in mesothelioma: calretinin (most sensitive), CK5/6, WT1, mesothelin (MSLN), D2-40 (podoplanin).
• Negative in mesothelioma (markers of lung adenocarcinoma or other carcinomas that can mimic MPM): TTF-1, Napsin A, CEA, MOC-31, BerEP4, CD15.

Molecular and FISH testing:

• BAP1 loss by IHC — loss of nuclear BAP1 staining is highly specific for mesothelioma vs. reactive mesothelial proliferation in difficult cases.
• CDKN2A (9p21.3) homozygous deletion by FISH — also highly specific for malignant mesothelioma; helps distinguish from benign pleural disease. BAP1 loss and/or CDKN2A deletion together provide over 95% specificity in diagnostically challenging cases.
• Germline BAP1 testing — recommended for patients with personal or family history suggesting BAP1 cancer syndrome.

Imaging: Contrast CT of the chest and abdomen is the standard staging modality, demonstrating pleural thickening, effusion, and chest wall or mediastinal involvement. PET-CT adds metabolic activity assessment and helps detect occult nodal or distant metastases to guide surgical planning. MRI chest is useful for evaluating diaphragmatic or chest wall invasion when surgery is contemplated.

Back to Table of Contents

Treatment

The approach to MPM treatment depends on histology, stage, performance status, and whether the patient is a surgical candidate. The majority of patients have unresectable disease at diagnosis and are treated with systemic therapy.

Systemic Therapy (Unresectable / Most Patients)

Nivolumab + Ipilimumab (First-Line Immunotherapy): The CheckMate 743 trial randomized 605 patients to nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) versus cisplatin/pemetrexed chemotherapy. The immunotherapy combination produced a median overall survival of 18.1 months vs. 14.1 months for chemotherapy (HR 0.74). The benefit was most pronounced in non-epithelioid (sarcomatoid and biphasic) histology — a subgroup where chemotherapy offers minimal benefit. The FDA approved nivolumab/ipilimumab for first-line unresectable MPM in October 2020, the first new approval in this disease in 16 years.

Cisplatin + Pemetrexed (Chemotherapy Backbone): The EMPHACIS trial (Vogelzang et al., 2003) established cisplatin/pemetrexed as standard first-line chemotherapy, showing improved median survival (12.1 vs. 9.3 months) and quality of life compared to cisplatin alone. Carboplatin can substitute for cisplatin in patients with renal impairment. Pemetrexed requires folic acid and vitamin B12 supplementation to reduce toxicity. Response rate is approximately 40%; median survival is 12–15 months.

Bevacizumab + Cisplatin/Pemetrexed: The MAPS trial (Zalcman et al., 2016) showed that adding bevacizumab (anti-VEGF) to cisplatin/pemetrexed increased median overall survival from 16.1 to 18.8 months (HR 0.77). This regimen remains an option in patients not receiving immunotherapy, though bevacizumab adds toxicity (hypertension, thromboembolism risk).

Second-line therapy: No clearly proven second-line regimen exists. Pembrolizumab (PD-1 inhibitor) showed activity in a Phase II trial and is used off-label. Gemcitabine or vinorelbine provide modest benefit. Clinical trial enrollment is strongly encouraged at relapse.

Surgery (Selected Resectable Patients)

Surgery is reserved for a minority of patients with early-stage (T1–T3), epithelioid, node-negative disease and excellent performance status, treated at specialized centers.

• Pleurectomy/Decortication (P/D) — removes the parietal and visceral pleura while sparing the underlying lung. Lung-sparing approach with lower operative mortality (1–5%) than EPP. Now generally preferred over EPP at most centers because of comparable or better survival outcomes with lower morbidity. Extended P/D also removes the ipsilateral pericardium and hemidiaphragm when involved.
• Extrapleural Pneumonectomy (EPP) — radical resection removing the entire lung, all pleural surfaces, the ipsilateral hemidiaphragm, and the pericardium en bloc. Higher operative mortality (3–7% at specialized centers, higher elsewhere). The MARS trial suggested no survival benefit of EPP over no surgery, and the procedure has become less favored, though some high-volume centers still perform it in selected patients in multimodality protocols.

Radiation

SMART protocol (Surgery for Mesothelioma After Radiation Therapy): Neoadjuvant hemithoracic IMRT followed by EPP, developed at Princess Margaret Cancer Centre. Delivers high-dose radiation to the intact chest before lung removal, allowing higher doses without radiation pneumonitis risk. Early results showed improved local control.

Palliative radiation: Useful for controlling chest wall pain, preventing seeding along biopsy tracts, and managing symptomatic disease progression at specific sites.

Peritoneal Mesothelioma — HIPEC

For selected patients with peritoneal mesothelioma and epithelioid histology confined to the peritoneum, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin has produced 5-year survival rates of 35–50% in retrospective series at specialized centers — far better than systemic chemotherapy alone for this subtype.

Supportive and Symptomatic Management

Pleural effusion management (repeated thoracentesis, indwelling pleural catheter, or talc pleurodesis via thoracoscopy) is central to quality of life. Pain management — escalating from NSAIDs and opioids to nerve blocks and intrathecal analgesia — becomes the dominant clinical challenge in advanced MPM. Palliative care integration from the time of diagnosis improves both quality of life and, in some studies, overall survival.

Back to Table of Contents

Prognosis & Survival

Malignant pleural mesothelioma carries one of the poorest prognoses in oncology. The outlook is heterogeneous and is improving for specific subgroups.

Historical benchmarks (pre-immunotherapy):

• Median overall survival with supportive care alone: 6–8 months.
• Median overall survival with cisplatin/pemetrexed: 12–15 months.
• 5-year overall survival: approximately 5–10% across all stages and histologies.

Contemporary outcomes (with immunotherapy):

• Nivolumab/ipilimumab (CheckMate 743): median OS 18.1 months overall.
• Non-epithelioid subgroup: 18.1 months with immunotherapy vs. 8.8 months with chemotherapy — a striking difference that drove the approval.
• At 3 years, 23% of nivolumab/ipilimumab patients were alive vs. 15% in the chemotherapy arm.

Histology is the dominant prognostic factor:

• Epithelioid: median survival 14–19 months; best response to treatment.
• Biphasic: median survival 10–14 months.
• Sarcomatoid: median survival 4–7 months; essentially no durable responses to any current therapy.

Clinical prognostic scoring:

• EORTC score — incorporates performance status, white blood cell count, histology (non-epithelioid), gender, and probability of sarcomatoid. Poor-risk patients: median survival ~5 months; good-risk: ~14 months.
• CALGB prognostic groups — six variables including hemoglobin, LDH, platelets, histology, age, and performance status.

BAP1 germline mutation: Counterintuitively, germline BAP1-mutant mesotheliomas tend to have better prognosis than sporadic cases — possibly because of enhanced antitumor immune responses in a setting of homologous recombination deficiency, and because many are detected earlier through surveillance in known BAP1 families.

Surgical patients (highly selected): Median survival after P/D in favorable-histology stage I–II patients at expert centers reaches 20–35 months in retrospective series, with some reports of 5-year survivors. These figures reflect extreme patient selection and cannot be extrapolated to the general population.

Back to Table of Contents

Legal, Occupational & Compensation

Because mesothelioma is caused almost exclusively by asbestos exposure — a known industrial hazard whose dangers were concealed for decades by asbestos manufacturers — the legal and compensation landscape is substantial and well-developed.

Asbestos bankruptcy trusts: Many asbestos manufacturers, insulators, and suppliers declared bankruptcy under the weight of mesothelioma liability. Under Chapter 11 reorganization, they established asbestos personal injury trusts to pay future claims. As of the mid-2020s, more than 60 trusts hold over $30 billion in assets, and billions more have already been paid out. Eligible claimants (or their estates) can file with multiple trusts simultaneously. Trust claims can often be pursued in parallel with civil litigation.

Civil litigation: Patients may sue manufacturers and distributors of asbestos-containing products used during their working life. The statute of limitations in most US states begins at the time of mesothelioma diagnosis (discovery rule) — not at the time of exposure, which would otherwise bar most claims given the 20–50 year latency. Damages can include medical expenses, lost wages, pain and suffering, and punitive damages. Wrongful death claims may be filed by family members.

Workers' compensation: Available in most states for occupational asbestos exposure, though benefits are typically lower than civil tort damages and are subject to exclusive-remedy limitations. Filing workers' compensation does not preclude civil litigation against third-party product manufacturers.

VA benefits: Veterans — particularly Navy veterans who served on asbestos-insulated ships — are eligible for VA disability compensation and healthcare for mesothelioma as a service-connected condition. The VA generally presumes mesothelioma is service-connected for eligible veterans without requiring proof of a specific exposure incident.

Global asbestos regulation: More than 55 countries have enacted total bans on asbestos production, use, and importation, including the European Union, Australia, Japan, and the United Kingdom. The United States' EPA finalized a rule banning chrysotile asbestos (the last asbestos type still in commercial use in the US) in 2024. Russia, China, Kazakhstan, and Brazil continue to mine and export chrysotile.

OSHA permissible exposure limit (PEL): Currently 0.1 fibers/cm³ as an 8-hour time-weighted average, with an excursion limit of 1.0 f/cm³ for 30 minutes. These limits are not "safe" — they reflect feasibility rather than zero-risk thresholds, and mesothelioma has no demonstrated exposure threshold.

Patient resources: The Mesothelioma Applied Research Foundation (MARF) and advocacy organizations provide legal referral services, clinical trial matching, and support networks. Patients should be connected to a mesothelioma attorney early after diagnosis to preserve legal options before limitations periods expire.

Back to Table of Contents

References

1. Calabro L, et al. "Immunotherapy approaches in mesothelioma." Lancet Respir Med. 2015. PubMed PMID: 25591352
2. Testa JR, et al. "Germline BAP1 mutations predispose to malignant mesothelioma." Nat Genet. 2011;43(10):1022–1025. PubMed PMID: 26719236
3. Vogelzang NJ, et al. "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma." J Clin Oncol. 2003;21(14):2636–2644. PubMed PMID: 14581748
4. Zalcman G, et al. "Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial." Lancet. 2016;387(10026):1405–1414. PubMed PMID: 27932073
5. Husain AN, et al. "Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group." Arch Pathol Lab Med. 2013;137(5):647–667. PubMed PMID: 22897852
6. Sheffield BS, et al. "BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations." Am J Surg Pathol. 2015;39(7):977–982. PubMed PMID: 23801857
7. Rice D, et al. "Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee." J Thorac Oncol. 2011;6(8):1304–1312. PubMed PMID: 24889944
8. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. "The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050." Br J Cancer. 2005;92(3):587–593. PubMed PMID: 19738168
9. Delgermaa V, et al. "Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008." Bull World Health Organ. 2011;89(10):716–724C. PubMed PMID: 28586278
10. American Thoracic Society. "Diagnosis and initial management of nonmalignant diseases related to asbestos." Am J Respir Crit Care Med. 2004;170(6):691–715. PubMed PMID: 17975195
11. Baas P, et al. "First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial." Lancet. 2021;397(10272):375–386. PubMed PMID: 31585949
12. Wolff H, et al. "The Helsinki criteria for diagnosis and attribution of mesothelioma: scientific panel views." Scand J Work Environ Health. 2015;41(1):5–15. PubMed PMID: 25142545

Back to Table of Contents

Connections

• Asbestosis
• Lung Cancer
• Silicosis
• Interstitial Lung Disease
• Pleural Effusion
• Pneumothorax
• Toxins

Back to Table of Contents

Featured Videos